Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Büke Celikdemir, Roland Houben, Thibault Kervarrec, Mahtab Samimi & David Schrama. (2023) Current and preclinical treatment options for Merkel cell carcinoma. Expert Opinion on Biological Therapy 0:0, pages 1-20.
Read now
Read now
Shweta Kamat, Jay Patel, Britny R. Brown & Ami Vyas. (2022) Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis. Cancer Investigation 40:9, pages 777-788.
Read now
Read now
Yao Xu, Kamal Hezam, Manasik Gumah Ali, Yang Wang & Juan Zhang. (2021) The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. Immunopharmacology and Immunotoxicology 43:3, pages 386-394.
Read now
Read now
Ahmed A. M. Abdelhafeez, Kyrillus S. Shohdy & Wael Ibrahim. (2020) Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis. Cancer Investigation 38:3, pages 150-157.
Read now
Read now
Articles from other publishers (25)
Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo & Jing Min Cheng. (2023) Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis. Frontiers in Pharmacology 14.
Crossref
Crossref
Yiru Zhang, Qigu Yao, Yong Pan, Xinru Fang, Haoying Xu, Tingxiao Zhao, Guangqi Zhu, Tianan Jiang, Shibo Li & Hongcui Cao. (2023) Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. Cancers 15:3, pages 682.
Crossref
Crossref
Qian Guo, Jian Gao, Hui Guo, Jun Xie & Jingmin Cheng. (2023) Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis. International Immunopharmacology 114, pages 109490.
Crossref
Crossref
Robin Maximilian Awad & Karine Breckpot. 2023.
Walid Shalata, Sarah Weissmann, Sapir Itzhaki Gabay, Kim Sheva, Omar Abu Saleh, Ashraf Abu Jama, Alexander Yakobson & Keren Rouvinov. (2022) A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers 14:21, pages 5451.
Crossref
Crossref
Gang Li, Sheng Gong, Ning Wang & Xiaojun Yao. (2022) Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report. Frontiers in Immunology 13.
Crossref
Crossref
Wissam Zam & Lina Ali. (2022) Immune Checkpoint Inhibitors in the Treatment of Cancer. Current Reviews in Clinical and Experimental Pharmacology 17:2, pages 103-113.
Crossref
Crossref
Michael H. Kroll, Cristhiam Rojas-Hernandez & Cassian Yee. (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139:25, pages 3594-3604.
Crossref
Crossref
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz & Iwona Lugowska. (2022) Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of Clinical Oncology 40:7, pages 762-771.
Crossref
Crossref
Angelika M. Starzer, Matthias Preusser & Anna S. Berghoff. (2022) Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Therapeutic Advances in Medical Oncology 14, pages 175883592210962.
Crossref
Crossref
Kohei Somekawa, Nobuyuki Horita, Ayami Kaneko, Yoichi Tagami, Nobuhiko Fukuda, Hiromi Matsumoto, Ho Namkoong, Yu Fujiwara, Kaoru Minegishi, Takeshi Fukumoto, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi & Takeshi Kaneko. (2022) Adverse events induced by nivolumab and ipilimumab combination regimens. Therapeutic Advances in Medical Oncology 14, pages 175883592110583.
Crossref
Crossref
M. A. Lyadova, V. K. Lyadov, O. A. Pardabekova, I. A. Pokataev, M. E. Ivannikov, Ya. V. Koroleva, E. S. Chernysheva & K. V. Lyadov. (2021) Results of combined nivolumab and ipilimumab therapy in patients with cancer. Meditsinskiy sovet = Medical Council:20, pages 18-23.
Crossref
Crossref
Pankaj Ahluwalia, Ashis K Mondal, Nikhil S Sahajpal, Mumtaz V Rojiani & Ravindra Kolhe. (2021) Gene signatures with therapeutic value: emerging perspective for personalized immunotherapy in renal cancer. Immunotherapy 13:18, pages 1535-1547.
Crossref
Crossref
Margaret M. Byrne, Mathew Lucas, Lori Pai, Janis Breeze & Susan K. Parsons. (2021) Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors. European Journal of Haematology 107:6, pages 650-657.
Crossref
Crossref
Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund & Henrik Schmidt. (2021) Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers 13:21, pages 5550.
Crossref
Crossref
Patrick O’Connell, Sean Hyslop, Maja K. Blake, Sarah Godbehere, Andrea Amalfitano & Yasser A. Aldhamen. (2021) SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. The Journal of Immunology 206:1, pages 193-205.
Crossref
Crossref
Ajay Tambe, Alina Basnet, Vikrant Tambe, Madhuri Badrinath & Rachana Mandru. (2021) Diplopia and Acute Vision Loss After Nivolumab Plus Ipilimumab Therapy. American Journal of Therapeutics 28:2, pages e246-e247.
Crossref
Crossref
Roshini S. Abraham. (2020) How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation. Hematology 2020:1, pages 661-672.
Crossref
Crossref
Alice C. Shieh, Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya & Sree Harsha Tirumani. (2019) Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. Abdominal Radiology 45:10, pages 3028-3035.
Crossref
Crossref
Pier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, Amin H Nassar, Ronan Flippot, Catherine Curran, Kerry L Kilbridge, Xiao X Wei, Bradley A McGregor, Toni Choueiri, Lauren C Harshman & Guru Sonpavde. (2020) Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 8:1, pages e000371.
Crossref
Crossref
Beiu, Giurcaneanu, Grumezescu, Holban, Popa & Mihai. (2020) Nanosystems for Improved Targeted Therapies in Melanoma. Journal of Clinical Medicine 9:2, pages 318.
Crossref
Crossref
Junichiro Ohira, Michi Kawamoto, Yoshio Sugino & Nobuo Kohara. (2020) A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine 99:15, pages e19741.
Crossref
Crossref
Yudai Ishikawa, Eiji Yoneyama, Akiyoshi Takaki, Norimasa Takahashi, Atsuo Ono, Atsushi Kato & Isao Adachi. (2019) Safety Evaluation of Retreatment with Immune Checkpoint Inhibitors免疫チェックポイント阻害薬再導入における安全性の検討. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 45:12, pages 659-666.
Crossref
Crossref
Arsen Osipov, May Tun Saung, Lei Zheng & Adrian G. Murphy. (2019) Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
T. Graham Norwood, Michelle J. Wang & Warner K. Huh. (2019) Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report. Gynecologic Oncology Reports 30, pages 100508.
Crossref
Crossref